Inpharmatica launches StARLITe and DrugStore

Inpharmatica has launched two new drug discovery databases - StARLITe and DrugStore.

Inpharmatica's chemogenomics database, StARLITe, contains high quality reported screening information for more than 300,000 compounds, their molecular targets and their biological activities. DrugStore is a unique, comprehensive and easily accessible knowledge-base covering key information on all FDA approved drugs.

The company has designed these databases to provide both chemists and biologists working in drug discovery research with important information about launched drugs and historically screened compounds. The databases allow searching by protein sequence, chemical structure and text. StARLITe is an extensive, highly curated and searchable database of current and historical published medicinal chemistry, while DrugStore provides the definitive view of drugs and drug properties. StARLITe and DrugStore adds to Inpharmatica's range of databases for drug discovery, which includes GPCR SARfari and Biopendium.

StARLITe and DrugStore are components of PharmaCarta, Inpharmatica's gene-to-candidate technology platform which integrates biology- and chemistry-based drug discovery activities. PharmaCarta optimises target selection based on druggability, and enables rapid identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics.

Commenting on the launch, John Lisle, CEO of Inpharmatica, said: 'StARLITe and DrugStore follow on the heels of Inpharmatica's recent launch of its GPCR SARfari database, which is already enjoying strong demand. These high-quality databases are an invaluable tool for discovery biologists and chemists alike.'